Odeth Barrett-Campbell, MD
Hematology & Oncology · Beckley, WVNPI 1306297999
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,570 of the $3,076 with a category attached, or 83.6%. It is spread thinly across 38 manufacturers, the largest accounting for just 8.4% — the pattern of someone who eats at a lot of different presentations.
Across 151 payments — averaging $20.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$257
- Johnson & Johnson$226
- Novartis$212
- Incyte Corporation$208
- E.r. Squibb & Sons, L.L.C.$199
- AbbVie$197
- plus $2K from 32 others
What the payments were for
- Food & beverage$2,57084%
- Education$50616%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 9 | $257 |
| Johnson & Johnson | 9 | $226 |
| Novartis | 11 | $212 |
| Incyte Corporation | 8 | $208 |
| E.r. Squibb & Sons, L.L.C. | 12 | $199 |
| AbbVie | 6 | $197 |
| Daiichi Sankyo Inc. | 22 | $189 |
| Seagen Inc. | 3 | $178 |
| Pfizer | 10 | $163 |
| Merck | 8 | $144 |
| Bristol Myers Squibb | 6 | $138 |
| GSK | 4 | $111 |
| Bayer | 5 | $98 |
| Stemline Therapeutics Inc. | 4 | $84 |
| Array Biopharma Inc | 3 | $66 |
| AstraZeneca(2 entities) | 3 | $56 |
| Telix Pharmaceuticals | 2 | $42 |
| Karyopharm Therapeutics Inc. | 2 | $41 |
| Pharmacosmos Therapeutics Inc. | 1 | $35 |
| Sobi, Inc | 2 | $35 |
| Tersera Therapeutics LLC | 1 | $31 |
| Myriad Genetic Laboratories, Inc. | 2 | $30 |
| Amgen | 2 | $29 |
| Tempus AI, Inc | 2 | $28 |
| Pharmaessentia USA Corporation | 1 | $27 |
| Shield Therapeutics Inc | 1 | $24 |
| Genentech USA, Inc. | 1 | $23 |
| Kyowa Kirin, Inc. | 1 | $22 |
| Taiho Oncology, Inc. | 1 | $22 |
| Jazz Pharmaceuticals Inc. | 1 | $22 |
| Coherus Oncology, Inc. | 1 | $21 |
| Deciphera Pharmaceuticals Inc. | 1 | $20 |
| Mirati Therapeutics, Inc. | 1 | $20 |
| ADC Therapeutics America, Inc. | 1 | $20 |
| Beone Medicines USA, Inc. | 1 | $18 |
| Foundation Medicine, Inc. | 1 | $14 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $14 |
| Blueprint Medicines Corporation | 1 | $13 |
How this compares
$3,076 in reported general payments places this provider in the 65th percentile of 72 hematology & oncology providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KeytrudaPembrolizumab | 28 | $310,930 |
| CalquenceAcalabrutinib Maleate | 13 | $191,394 |
| PadcevEnfortumab Vedotin-Ejfv | 11 | $165,840 |
| EliquisApixaban | 22 | $15,267 |
| Oxycodone Hcl | 19 | $128 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 12 | $123 |
| Ondansetron Hcl | 16 | $117 |
| Prochlorperazine Maleate | 11 | $97 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckKeytruda | $144 | $310,93028 claims |
| AstraZenecaCalquence | $56 | $191,39413 claims |
| Seagen Inc.Padcev | $178 | $165,84011 claims |
| PfizerEliquis | $163 | $15,26722 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 72 hematology & oncology providers in West Virginia.
Other hematology & oncology in Beckley
- Venkataprasanth ReddyBeckley$2K
- Damian SilberminsHuntington$277K
- Abraham KanateMorgantown$169K
- Salman OsmanBridgeport$118K
- Ashkan EmadiMorgantown$88K
- Konstantinos SdrimasMorgantown$81K
- Arvinder BirHuntington$74K
- Bhavana BhatnagarWheeling$72K
- Ihtishaam QaziMorgantown$18K
- Matias ValsecchiHuntington$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.